Recommendations Updated for H. pylori Treatment in Adults

This article originally appeared here.
Share this content:
Recommendations Updated for <i>H. pylori</i> Treatment in Adults
Recommendations Updated for H. pylori Treatment in Adults

TUESDAY, July 12, 2016 (HealthDay News) -- Recommendations have been updated for treatment of Helicobacter pylori in adults, according to a consensus statement published in the July issue of Gastroenterology.

Carlo A. Fallone, M.D., from the McGill University Health Centre in Montreal, and colleagues conducted a systematic literature review and developed specific, updated recommendations for eradication therapy in adults with H. pylori infection.

The researchers strongly recommend that all H. pylori regimens should be given for 14 days because of the increasing failure of therapy. Concomitant nonbismuth quadruple therapy (proton pump inhibitor [PPI] + amoxicillin + metronidazole + clarithromycin [PAMC]) and traditional bismuth quadruple therapy (PPI + bismuth + metronidazole + tetracycline [PBMT]) were included as recommended first-line strategies. Use of PPI triple therapy (PPI + clarithromycin + amoxicillin or metronidazole) should be limited to regions with low resistance to clarithromycin or high eradication success with these regimens. PBMT and levofloxacin-containing therapy were included as recommended rescue therapies. Rifabutin therapy should be used only for patients who have failed to respond to three or more previous treatment regimens.

"Optimal treatment of H. pylori infection requires careful attention to local antibiotic resistance and eradication patterns," the authors write. "The quadruple therapies PAMC or PBMT should play a more prominent role in eradication of H. pylori infection, and all treatments should be given for 14 days."

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters


More in Home

First Opioid Lawsuit Targeting Pharmacy Benefit Managers

First Opioid Lawsuit Targeting Pharmacy Benefit Managers

First lawsuit mentions three largest PBMs; PBMs likely to be increasingly targeted in litigation

Opioids Tied to Adverse Outcomes in Hemodialysis Patients

Opioids Tied to Adverse Outcomes in Hemodialysis Patients

Increased risks of altered mental status, falls, and fractures; risk present even at low doses of opioids

Prescribing of Gluten-Free Foods Declining in England

Prescribing of Gluten-Free Foods Declining in England

Substantial variation in prescribing practices seen by locality of practice

is free, fast, and customized just for you!

Already a member?

Sign In Now »